According to the latest market report published by Acute Market Reports “Tardive Dyskinesia (TD) Treatment Drugs Market - Growth, Future Prospects and Competitive Analysis, 2021 - 2029” the global tardive dyskinesia (TD) treatment drugs market, expanding at a CAGR of 3.7% from 2021 to 2029.
Browse the full report Tardive Dyskinesia (TD) Treatment Drugs Market - Growth, Future Prospects and Competitive Analysis, 2021 – 2029 report at https://www.acutemarketreports.com/report/tardive-dyskinesia-td-treatment-drugs-market
Market Insights
Tardive dyskinesia (TD) treatment drugs market is expected to show significant market growth over the forecast period due to increase in incidence of TD, rising number of antipsychotic prescriptions, developing healthcare infrastructure and presence of late stage pipeline molecule. The global TD treatment drugs market is categorized on the basis of drug type such as valbenazine, deutetrabenazine and others (benzodiazepines, botulinum toxin, vitamin E, amantadine, levodopa, reserpine, dopamine-depleting agents and calcium channel blockers etc.). It is observed that the demand for valbenazine and deutetrabenazine is highest in market due to the efficacy and target specificity. Valbenazine and deutetrabenazine were approved in 2020. Furthermore, being the only approved drugs in the market, these drugs will experience significant demand.
Neurocrine Biosciences announced that the recently approved, Ingrezza (valbenazine) achieved $45.8 million net sales in third quarter in 2020. Expected launch of pipeline drug such as SNC-102 (Synchroneuron) would further drive the market growth during forecast period. Currently, North America leads the global TD treatment drugs market due to higher cost of therapeutics, early diagnosis of the disease and increase in prevalence of TD. It is predicted that TD treatment drugs market in Asia Pacific will grow significantly in coming years due to growing number of affected population and emerging healthcare infrastructure.
Market Competition Assessment:
Currently, only two drugs Valbenazine by Neurocrine Biosciences, Inc. and Deutetrabenazine by Teva Pharmaceutical Industries Ltd. are approved by US-FDA for the treatment of TD. Key players involved in R&D activities are Synchroneuron Inc. (SNC-102) and Auspex Pharmaceuticals (SD–809).
